CALIXAR will present the new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest. The aim of this fundraising is for CALIXAR to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth €70bn by 2025.
About the Digital 20th Annual BEF :
The 20th Annual Biotech in Europe Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage, and public companies with leading investors, analysts, money managers, and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.